MA49727A - Anticorps et polypeptides dirigés contre cd127 - Google Patents
Anticorps et polypeptides dirigés contre cd127Info
- Publication number
- MA49727A MA49727A MA049727A MA49727A MA49727A MA 49727 A MA49727 A MA 49727A MA 049727 A MA049727 A MA 049727A MA 49727 A MA49727 A MA 49727A MA 49727 A MA49727 A MA 49727A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- directed against
- polypeptides directed
- diagnostic applications
- therapeutic
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 abstract 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne le domaine des anticorps utiles dans des applications thérapeutiques et de diagnostic ciblant le cd127, la chaîne alpha du récepteur il7, et fournit en particulier des anticorps monoclonaux humanisés contre le cd127, en particulier le cd127 humain, leurs utilisations thérapeutiques et des applications de diagnostic.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306655 | 2016-12-09 | ||
| PCT/EP2017/081911 WO2018104483A1 (fr) | 2016-12-09 | 2017-12-07 | Anticorps et polypeptides dirigés contre cd127 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49727A true MA49727A (fr) | 2019-10-16 |
| MA49727B1 MA49727B1 (fr) | 2021-05-31 |
Family
ID=57796143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49727A MA49727B1 (fr) | 2016-12-09 | 2017-12-07 | Anticorps et polypeptides dirigés contre cd127 |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US11098128B2 (fr) |
| EP (1) | EP3551664B1 (fr) |
| JP (1) | JP6986559B2 (fr) |
| KR (1) | KR102306366B1 (fr) |
| CN (1) | CN110392695B (fr) |
| AR (1) | AR110326A1 (fr) |
| AU (1) | AU2017373819B2 (fr) |
| BR (1) | BR112019010595A2 (fr) |
| CA (1) | CA3042582C (fr) |
| CL (1) | CL2019001530A1 (fr) |
| CO (1) | CO2019005909A2 (fr) |
| CR (1) | CR20190273A (fr) |
| CY (1) | CY1124153T1 (fr) |
| DK (1) | DK3551664T3 (fr) |
| EA (1) | EA201991005A1 (fr) |
| ES (1) | ES2867900T3 (fr) |
| HR (1) | HRP20210697T1 (fr) |
| HU (1) | HUE054206T2 (fr) |
| IL (1) | IL266837B (fr) |
| LT (1) | LT3551664T (fr) |
| MA (1) | MA49727B1 (fr) |
| MD (1) | MD3551664T2 (fr) |
| MX (1) | MX2019006577A (fr) |
| MY (1) | MY190770A (fr) |
| NZ (1) | NZ753213A (fr) |
| PE (1) | PE20191152A1 (fr) |
| PH (1) | PH12019501285A1 (fr) |
| PL (1) | PL3551664T3 (fr) |
| PT (1) | PT3551664T (fr) |
| RS (1) | RS61808B1 (fr) |
| RU (1) | RU2769352C2 (fr) |
| SA (1) | SA519401906B1 (fr) |
| SI (1) | SI3551664T1 (fr) |
| TW (1) | TWI777996B (fr) |
| UA (1) | UA126386C2 (fr) |
| UY (1) | UY37511A (fr) |
| WO (1) | WO2018104483A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7348074B2 (ja) | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| BR112021014106A2 (pt) * | 2019-01-22 | 2021-10-13 | Bristol-Myers Squibb Company | Anticorpos contra subunidade alfa de il-7r e usos dos mesmos |
| JP2022537780A (ja) * | 2019-06-21 | 2022-08-29 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| EP3986931A1 (fr) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020380296A1 (en) | 2019-11-05 | 2022-06-16 | Medikine Inc. | IL-2RβγC binding compounds |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| WO2023232826A1 (fr) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | Biomarqueurs de l'activité du modulateur de l'il7r |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| SG182590A1 (en) * | 2010-01-28 | 2012-08-30 | Glaxo Group Ltd | Cd127 binding proteins |
| AR080291A1 (es) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (fr) | 2011-10-19 | 2013-04-24 | Effimune | Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments |
| EP2955196A1 (fr) | 2014-06-10 | 2015-12-16 | Effimune | Anticorps dirigés contre CD127 |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active IP Right Grant
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 BR BR112019010595A patent/BR112019010595A2/pt unknown
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 UY UY0001037511A patent/UY37511A/es active IP Right Grant
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/fr active Active
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/fr active Search and Examination
- 2017-12-07 CA CA3042582A patent/CA3042582C/fr active Active
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
-
2019
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
- 2019-06-07 PH PH12019501285A patent/PH12019501285A1/en unknown
-
2021
- 2021-05-05 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49727B1 (fr) | Anticorps et polypeptides dirigés contre cd127 | |
| MA43859A (fr) | Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion | |
| PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| MA45029A (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
| PH12018501177A1 (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
| MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| UA114277C2 (uk) | Антиангіогенна терапія для лікування раку яєчника | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| PH12019501319A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
| CY1124922T1 (el) | Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| BR112018009004A8 (pt) | conjugados anti-cd3-folato e seus usos | |
| MX2014013678A (es) | Agentes para neutralizacion de influenza. | |
| EA201891608A1 (ru) | Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| EA201891610A1 (ru) | Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 |